153 related articles for article (PubMed ID: 32635536)
1. Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma.
Imai K; Takai K; Miwa T; Taguchi D; Hanai T; Suetsugu A; Shiraki M; Shimizu M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635536
[TBL] [Abstract][Full Text] [Related]
2. Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
Imai K; Takai K; Miwa T; Taguchi D; Hanai T; Suetsugu A; Shiraki M; Shimizu M
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31430945
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates.
Imai K; Takai K; Unome S; Miwa T; Hanai T; Suetsugu A; Shimizu M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686497
[TBL] [Abstract][Full Text] [Related]
4. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia.
Han J; Tang M; Lu C; Shen L; She J; Wu G
Clin Nutr; 2021 Sep; 40(9):5156-5161. PubMed ID: 34461589
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
Cancer Manag Res; 2018; 10():2231-2239. PubMed ID: 30100754
[TBL] [Abstract][Full Text] [Related]
7. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.
Ebadi M; Tandon P; Moctezuma-Velazquez C; Ghosh S; Baracos VE; Mazurak VC; Montano-Loza AJ
J Hepatol; 2018 Sep; 69(3):608-616. PubMed ID: 29709682
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
[TBL] [Abstract][Full Text] [Related]
9. Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis.
Ha NB; Cho SJ; Mohamad Y; Kent D; Jun G; Wong R; Swarnakar V; Lin S; Maher JJ; Lai JC
Dig Dis Sci; 2022 Jul; 67(7):3436-3444. PubMed ID: 34136974
[TBL] [Abstract][Full Text] [Related]
10. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma.
Saeki I; Yamasaki T; Maeda M; Kawano R; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
Liver Cancer; 2018 Oct; 7(4):359-371. PubMed ID: 30488024
[TBL] [Abstract][Full Text] [Related]
11. U-shaped relationship between subcutaneous adipose tissue index and mortality in liver cirrhosis.
Zhu M; Li H; Yin Y; Ding M; Philips CA; Romeiro FG; Qi X
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):508-516. PubMed ID: 36577511
[TBL] [Abstract][Full Text] [Related]
12. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
[TBL] [Abstract][Full Text] [Related]
13. Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer.
Nakano O; Kawai H; Kobayashi T; Kohisa J; Ikarashi S; Hayashi K; Yokoyama J; Terai S
Cancer Med; 2021 Jul; 10(13):4291-4301. PubMed ID: 33993635
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not.
Imai K; Takai K; Unome S; Miwa T; Hanai T; Suetsugu A; Shimizu M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275883
[TBL] [Abstract][Full Text] [Related]
15. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
[TBL] [Abstract][Full Text] [Related]
16. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
17. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
Montano-Loza AJ; Mazurak VC; Ebadi M; Meza-Junco J; Sawyer MB; Baracos VE; Kneteman N
Hepatology; 2018 Mar; 67(3):914-923. PubMed ID: 29023899
[TBL] [Abstract][Full Text] [Related]
18. Visceral Adipose Tissue Index and Hepatocellular Carcinoma Are Independent Predictors of Outcome in Patients with Cirrhosis Having Endoscopic Treatment for Esophageal Varices.
Kimura N; Tsuchiya A; Oda C; Kimura A; Hosaka K; Tominaga K; Hayashi K; Yokoyama J; Terai S
Dig Dis; 2021; 39(1):58-65. PubMed ID: 32450556
[TBL] [Abstract][Full Text] [Related]
19. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study.
Maurits JSF; Sedelaar JPM; Mulders PFA; Aben KKH; Kiemeney LALM; Vrieling A
Clin Nutr; 2022 Jan; 41(1):131-143. PubMed ID: 34872047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
